PDTs, Biosimilars, Hot Topics at AMCP meeting | AMCP 2023
Jeffrey Casberg on Breakthrough Ophthalmic Drugs that Payers, Pharmacists Should Pay Attention To
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
Beta Thalassemia Requires Specialized Management for Patients, Payors and Pharmacists
Exclusive: Profiling Manufacturers’ Limited and Exclusive Pharmacy Networks for Specialty Drugs
Drug Pathways, Potential Mechanisms of Resistance in PARP Inhibition
IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022
High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023
California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars
Biogen/ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
6 Payor Tactics to Control Drug Spending
Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
Payer Management Tools and Trends for Biosimilars in the US
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Upcoming Generics Provide New Considerations and Opportunities for Savings
Jeffery Casberg Previews His Presentations at AMCP 2022
Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022